Tags

Type your tag names separated by a space and hit enter

Treatment Mode Preferences in Psoriatic Arthritis: A Qualitative Multi-Country Study.
Patient Prefer Adherence. 2020; 14:949-961.PP

Abstract

Objective

Qualitative research exploring patient preferences regarding the mode of treatment administration for psoriatic arthritis (PsA) is limited. We report patient preferences and their reasons across PsA treatment modes.

Methods

In this global, cross-sectional, qualitative study, interviews were conducted with adult patients with PsA in Brazil, France, Germany, Italy, Spain, the UK, and the US. Patients were currently taking a disease-modifying antirheumatic drug (DMARD). Patients indicated the order and strength of preference (0-100; 100 = strongest) across four modes of treatment administration: oral (once daily), self-injection (weekly), clinic injection (weekly), and infusion (monthly); reasons for preferences were qualitatively assessed. Descriptive statistics were reported. Fisher's exact tests and t-tests were conducted for treatment mode outcomes.

Results

Overall, 85 patients were interviewed (female, 60.0%; mean age, 49.8 years). First-choice ranking (%) and mean [standard deviation] preference points were: oral (49.4%; 43.9 [31.9]); self-injection (34.1%; 32.4 [24.8]); infusion (15.3%; 14.5 [20.0]); clinic injection (1.2%; 9.2 [10.0]). Of 48 (56.5%) patients with a strong first-choice preference (ie point allocation ≥60), 66.7% chose oral administration. Self-injection was most often selected as second choice (51.8%), clinic injection as third (49.4%), and infusion as fourth (47.1%). Oral administration was the first-choice preference in the US (88.0% vs 38.0% in Europe). The most commonly reported reason for oral administration as the first choice was speed and ease of administration (76.2%); for self-injection, this was convenience (75.9%). The most commonly reported reason for avoiding oral administration was concern about possible drug interactions (63.6%); for self-injection, this was a dislike of needles or the injection process (66.7%).

Conclusion

Patients with PsA preferred oral treatment administration, followed by self-injection; convenience factors were common reasons for these preferences. Overall, 43.5% of patients did not feel strongly about their first-choice preference and may benefit from discussions with healthcare professionals about PsA treatment administration options.

Authors+Show Affiliations

Division of Rheumatology, Department of Internal Medicine 3, Medical University of Vienna, Vienna, Austria.Cleveland Clinic, Department of Rheumatic and Immunologic Diseases, Cleveland, OH, USA.Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.Serviço de Reumatología, Universidade Federal de Uberlândia, Uberlândia, Minas Gerais, Brazil.Patient Representative, Oslo, Norway.Inflammation & Immunology, Pfizer Pharma GmbH, Berlin, Germany.Inflammation & Immunology, Pfizer Inc, Collegeville, PA, USA.Statistics, Pfizer Inc, Groton, CT, USA.RTI Health Solutions, Research Triangle Park, NC, USA.RTI Health Solutions, Research Triangle Park, NC, USA.Health Economics & Outcomes Research, Pfizer Inc, Groton, CT, USA.Medical Affairs, Pfizer Inc, Montreal, QC, Canada.

Pub Type(s)

Journal Article

Language

eng

PubMed ID

32606613

Citation

Aletaha, Daniel, et al. "Treatment Mode Preferences in Psoriatic Arthritis: a Qualitative Multi-Country Study." Patient Preference and Adherence, vol. 14, 2020, pp. 949-961.
Aletaha D, Husni ME, Merola JF, et al. Treatment Mode Preferences in Psoriatic Arthritis: A Qualitative Multi-Country Study. Patient Prefer Adherence. 2020;14:949-961.
Aletaha, D., Husni, M. E., Merola, J. F., Ranza, R., Bertheussen, H., Lippe, R., Young, P. M., Cappelleri, J. C., Brown, T. M., Ervin, C., Hsu, M. A., & Fallon, L. (2020). Treatment Mode Preferences in Psoriatic Arthritis: A Qualitative Multi-Country Study. Patient Preference and Adherence, 14, 949-961. https://doi.org/10.2147/PPA.S242336
Aletaha D, et al. Treatment Mode Preferences in Psoriatic Arthritis: a Qualitative Multi-Country Study. Patient Prefer Adherence. 2020;14:949-961. PubMed PMID: 32606613.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Treatment Mode Preferences in Psoriatic Arthritis: A Qualitative Multi-Country Study. AU - Aletaha,Daniel, AU - Husni,M Elaine, AU - Merola,Joseph F, AU - Ranza,Roberto, AU - Bertheussen,Heidi, AU - Lippe,Ralph, AU - Young,Pamela M, AU - Cappelleri,Joseph C, AU - Brown,T Michelle, AU - Ervin,Claire, AU - Hsu,Ming-Ann, AU - Fallon,Lara, Y1 - 2020/06/08/ PY - 2019/12/17/received PY - 2020/05/07/accepted PY - 2020/7/2/entrez PY - 2020/7/2/pubmed PY - 2020/7/2/medline KW - patient preference KW - psoriatic arthritis KW - qualitative research KW - treatment administration SP - 949 EP - 961 JF - Patient preference and adherence JO - Patient Prefer Adherence VL - 14 N2 - Objective: Qualitative research exploring patient preferences regarding the mode of treatment administration for psoriatic arthritis (PsA) is limited. We report patient preferences and their reasons across PsA treatment modes. Methods: In this global, cross-sectional, qualitative study, interviews were conducted with adult patients with PsA in Brazil, France, Germany, Italy, Spain, the UK, and the US. Patients were currently taking a disease-modifying antirheumatic drug (DMARD). Patients indicated the order and strength of preference (0-100; 100 = strongest) across four modes of treatment administration: oral (once daily), self-injection (weekly), clinic injection (weekly), and infusion (monthly); reasons for preferences were qualitatively assessed. Descriptive statistics were reported. Fisher's exact tests and t-tests were conducted for treatment mode outcomes. Results: Overall, 85 patients were interviewed (female, 60.0%; mean age, 49.8 years). First-choice ranking (%) and mean [standard deviation] preference points were: oral (49.4%; 43.9 [31.9]); self-injection (34.1%; 32.4 [24.8]); infusion (15.3%; 14.5 [20.0]); clinic injection (1.2%; 9.2 [10.0]). Of 48 (56.5%) patients with a strong first-choice preference (ie point allocation ≥60), 66.7% chose oral administration. Self-injection was most often selected as second choice (51.8%), clinic injection as third (49.4%), and infusion as fourth (47.1%). Oral administration was the first-choice preference in the US (88.0% vs 38.0% in Europe). The most commonly reported reason for oral administration as the first choice was speed and ease of administration (76.2%); for self-injection, this was convenience (75.9%). The most commonly reported reason for avoiding oral administration was concern about possible drug interactions (63.6%); for self-injection, this was a dislike of needles or the injection process (66.7%). Conclusion: Patients with PsA preferred oral treatment administration, followed by self-injection; convenience factors were common reasons for these preferences. Overall, 43.5% of patients did not feel strongly about their first-choice preference and may benefit from discussions with healthcare professionals about PsA treatment administration options. SN - 1177-889X UR - https://www.unboundmedicine.com/medline/citation/32606613/Treatment_Mode_Preferences_in_Psoriatic_Arthritis:_A_Qualitative_Multi-Country_Study L2 - https://dx.doi.org/10.2147/PPA.S242336 DB - PRIME DP - Unbound Medicine ER -
Try the Free App:
Prime PubMed app for iOS iPhone iPad
Prime PubMed app for Android
Prime PubMed is provided
free to individuals by:
Unbound Medicine.